Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rituximab + paclitaxel protein-bound + pegylated liposomal doxorubicin
- Development stage
- Preclinical
- Lead developer
- Genentech
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This is a combination regimen consisting of three agents: rituximab, a monoclonal antibody targeting CD20 on B cells; paclitaxel protein-bound (also known as albumin-bound or nab-paclitaxel), a taxane-class antimicrotubule agent delivered via nanoparticle albumin binding to enhance delivery and reduce solvent-related toxicity; and pegylated liposomal doxorubicin, an anthracycline chemotherapeutic encapsulated in PEG-coated liposomes for improved pharmacokinetics and reduced cardiotoxicity. This combination has been studied for the treatment of relapsed or refractory diffuse large B-cell lymphoma, leveraging the immunotherapeutic effect of rituximab with two nanoparticle-formulated cytotoxics that disrupt cell division and DNA integrity[1][2][3].
- Brand names
- AbraxaneDoxil
- Other names
- albumin-bound paclitaxelnab-paclitaxelPLDliposomal doxorubicin
02
Targets
CD20 (B-lymphocyte antigen CD20)TUBB (Tubulin (alpha and beta subunits))TOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on rituximab + paclitaxel protein-bound + pegylated liposomal doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rituximab + paclitaxel protein-bound + pegylated liposomal doxorubicin.